Announcements Trials
Browse Landscape

Phase

Phase 1/2 8Phase 2 7Phase 1 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3CNS 2Gastrointestinal 1

Conditions

Glioblastoma 107Gliosarcoma 48Glioma 41Brain Neoplasms 38Astrocytoma 38Central Nervous System Neoplasms 30Oligodendroglioma 27Medulloblastoma 15Melanoma 14Neuroblastoma 13Ependymoma 11Neoplasms 10Familial ependymoma 8Choroid Plexus Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Sarcoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Sarcoma, Ewing 5Recurrence 5Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Lymphoma 4Glioma, Subependymal 4Spinal Cord Neoplasms 3Rhabdomyosarcoma 3Pinealoma 3

Interventions

Melphalan 4Irinotecan 4Filgrastim 4Cyclophosphamide 4Busulfan 4fludarabine 3Topotecan 3Temozolomide 3Granulocyte Colony-Stimulating Factor 3pegfilgrastim 2liposomal doxorubicin 2Thiotepa 2Sirolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1ribociclib 1regorafenib 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1mocetinostat 1lexatumumab 1irinotecan sucrosofate 1fludarabine phosphate 1cixutumumab 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Rhabdomyosarcoma × Temozolomide × Clear all
NCT04337177 2026-05-11

Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Valent Technologies, LLC

Phase 1 Active not recruiting
20 enrolled
CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Massachusetts General Hospital

Phase 1 Completed
49 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Ewing

NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Novartis

Phase 1 Terminated
12 enrolled
CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚔